Balyasny Asset Management LLC Eye Point Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 67,073 shares of EYPT stock, worth $491,645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,073
Previous 116,195
42.28%
Holding current value
$491,645
Previous $1.01 Million
47.03%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EYPT
# of Institutions
150Shares Held
58MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$61 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$37.9 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$29.4 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$27.8 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$27.6 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $250M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...